{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,21]],"date-time":"2026-03-21T02:54:45Z","timestamp":1774061685594,"version":"3.50.1"},"reference-count":63,"publisher":"Wiley","issue":"6","license":[{"start":{"date-parts":[[2015,9,1]],"date-time":"2015-09-01T00:00:00Z","timestamp":1441065600000},"content-version":"tdm","delay-in-days":1542,"URL":"http:\/\/doi.wiley.com\/10.1002\/tdm_license_1.1"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2011,11]]},"DOI":"10.1111\/j.1439-0507.2011.02038.x","type":"journal-article","created":{"date-parts":[[2011,6,13]],"date-time":"2011-06-13T04:13:12Z","timestamp":1307938392000},"page":"e679-e685","source":"Crossref","is-referenced-by-count":28,"title":["Recent updates in oral terbinafine: its use in onychomycosis and tinea capitis in the US"],"prefix":"10.1111","volume":"54","author":[{"given":"Lauren","family":"Van Duyn Graham","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Boni E.","family":"Elewski","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"311","published-online":{"date-parts":[[2011,6,12]]},"reference":[{"key":"10.1111\/j.1439-0507.2011.02038.x-BIB1|cit1","doi-asserted-by":"crossref","first-page":"403","DOI":"10.1179\/joc.2009.21.4.403","article-title":"In vitro susceptibility of nondermatophyte molds isolated from onychomycosis to antifungal drugs","volume":"21","author":"Trovato","year":"2009","journal-title":"J Chemother"},{"key":"10.1111\/j.1439-0507.2011.02038.x-BIB2|cit2","doi-asserted-by":"crossref","first-page":"769","DOI":"10.1093\/jac\/dkq023","article-title":"European Surveillance of Antimicrobial Consumption (ESAC): outpatient systemic antimycotic and antifungal use in Europe","volume":"65","author":"Adriaenssens","year":"2010","journal-title":"J Antimicrob Chemother"},{"key":"10.1111\/j.1439-0507.2011.02038.x-BIB3|cit3","doi-asserted-by":"crossref","first-page":"2","DOI":"10.1111\/j.1365-2133.1992.tb00001.x","article-title":"Terbinafine: mode of action and properties of the squalene epoxidase inhibition","volume":"126","author":"Ryder","year":"1992","journal-title":"Br J Dermatol"},{"key":"10.1111\/j.1439-0507.2011.02038.x-BIB4|cit4","doi-asserted-by":"crossref","first-page":"404","DOI":"10.5694\/j.1326-5377.2007.tb01313.x","article-title":"Antifungal agents","volume":"187","author":"Chen","year":"2007","journal-title":"Med J Aust"},{"key":"10.1111\/j.1439-0507.2011.02038.x-BIB5|cit5","doi-asserted-by":"crossref","DOI":"10.1093\/clinids\/2.4.520","article-title":"Mechanism of action of antifungal drugs, with special reference to the imidazole derivatives [with discussion]","volume":"2","author":"Borgers","year":"1980","journal-title":"Rev Infect Dis"},{"key":"10.1111\/j.1439-0507.2011.02038.x-BIB6|cit6","first-page":"299","article-title":"Safety and tolerability of oral antifungal agents in the treatment of fungal nail disease: a proven reality","volume":"1","author":"Elewski","year":"2005","journal-title":"Ther Clin Risk Manag"},{"key":"10.1111\/j.1439-0507.2011.02038.x-BIB7|cit7","doi-asserted-by":"crossref","first-page":"770","DOI":"10.1016\/S0090-9556(24)15224-5","article-title":"Potent inhibition of cytochrome P-450 2D6-mediated dextromethorphan O-demethylation by terbinafine","volume":"27","author":"Abdel-Rahman","year":"1999","journal-title":"Drug Metab Dispos"},{"key":"10.1111\/j.1439-0507.2011.02038.x-BIB8|cit8","doi-asserted-by":"crossref","first-page":"465","DOI":"10.1016\/S0009-9236(99)70065-2","article-title":"Investigation of terbinafine as a CYP2D6 inhibitor in vivo","volume":"65","author":"Abdel-Rahman","year":"1999","journal-title":"Clin Pharmacol Ther"},{"key":"10.1111\/j.1439-0507.2011.02038.x-BIB9|cit9","doi-asserted-by":"crossref","first-page":"680","DOI":"10.1097\/01.ftd.0000175910.68539.33","article-title":"Prolonged pharmacokinetic drug interaction between terbinafine and amitriptyline","volume":"27","author":"Castberg","year":"2005","journal-title":"Ther Drug Monit"},{"key":"10.1111\/j.1439-0507.2011.02038.x-BIB10|cit10","doi-asserted-by":"crossref","first-page":"1712","DOI":"10.1345\/aph.1C083","article-title":"Pharmacokinetic interaction between nortriptyline and terbinafine","volume":"36","author":"Van Der Kuy","year":"2002","journal-title":"Ann Pharmacother"},{"key":"10.1111\/j.1439-0507.2011.02038.x-BIB11|cit11","doi-asserted-by":"crossref","first-page":"51","DOI":"10.1007\/s00228-006-0217-9","article-title":"Terbinafine increases the plasma concentration of paroxetine after a single oral administration of paroxetine in healthy subjects","volume":"63","author":"Yasui-Furukori","year":"2007","journal-title":"Eur J Clin Pharmacol"},{"key":"10.1111\/j.1439-0507.2011.02038.x-BIB12|cit12","doi-asserted-by":"crossref","first-page":"1211","DOI":"10.1177\/009127002762491299","article-title":"Effect of terbinafine on the pharmacokinetics and pharmacodynamics of desipramine in healthy volunteers identified as cytochrome P450 2D6 (CYP2D6) extensive metabolizers","volume":"42","author":"Madani","year":"2002","journal-title":"J Clin Pharmacol"},{"key":"10.1111\/j.1439-0507.2011.02038.x-BIB13|cit13","volume-title":"Lamisil (terbinafine hydrochloride) Prescribing Information","author":"Novartis Pharmaceuticals Corporation","year":"2005"},{"key":"10.1111\/j.1439-0507.2011.02038.x-BIB14|cit14","doi-asserted-by":"crossref","first-page":"1213","DOI":"10.1001\/archderm.133.10.1213","article-title":"Safety of oral terbinafine: results of a postmarketing surveillance study in 25,884 patients","volume":"133","author":"Hall","year":"1997","journal-title":"Arch Dermatol"},{"key":"10.1111\/j.1439-0507.2011.02038.x-BIB15|cit15","doi-asserted-by":"crossref","first-page":"8","DOI":"10.5070\/D375C2W9P2","article-title":"Terbinafine-induced acute generalised exanthematous pustulosis (AGEP) responsive to high dose intravenous corticosteroid","volume":"15","author":"Ibrahimi","year":"2009","journal-title":"Dermatol Online J"},{"key":"10.1111\/j.1439-0507.2011.02038.x-BIB16|cit16","doi-asserted-by":"crossref","first-page":"1133","DOI":"10.1046\/j.1365-2133.1998.2576s.x","article-title":"Onychomycosis caused by infection with Paecilomyces lilacinus","volume":"139","author":"Fletcher","year":"1998","journal-title":"Br J Dermatol"},{"key":"10.1111\/j.1439-0507.2011.02038.x-BIB17|cit17","doi-asserted-by":"crossref","first-page":"465","DOI":"10.18388\/abp.1995_4900","article-title":"Ergosterol biosynthesis inhibition: a target for antifungal agents","volume":"42","author":"Barrett-Bee","year":"1995","journal-title":"Acta Biochim Pol"},{"key":"10.1111\/j.1439-0507.2011.02038.x-BIB18|cit18","first-page":"311","article-title":"Comparison of the in vitro activity of terbinafine and lanoconazole against dermatophytes","volume":"53","author":"Ghannoum","year":"2010","journal-title":"Mycoses"},{"key":"10.1111\/j.1439-0507.2011.02038.x-BIB19|cit19","doi-asserted-by":"crossref","first-page":"259","DOI":"10.2165\/00003495-199243020-00010","article-title":"Terbinafine: a review of its pharmacodynamic and pharmacokinetic properties, and therapeutic potential in superficial mycoses","volume":"43","author":"Balfour","year":"1992","journal-title":"Drugs"},{"key":"10.1111\/j.1439-0507.2011.02038.x-BIB20|cit20","doi-asserted-by":"crossref","first-page":"121","DOI":"10.1111\/j.1365-2230.1994.tb01138.x","article-title":"Levels of terbinafine in plasma, stratum corneum, dermis-epidermis (without stratum corneum), sebum, hair and nails during and after 250\u2003mg terbinafine orally once daily for 7 and 14\u2003days","volume":"19","author":"Faergemann","year":"1994","journal-title":"Clin Exp Dermatol"},{"issue":"Suppl. 39","key":"10.1111\/j.1439-0507.2011.02038.x-BIB21|cit21","doi-asserted-by":"crossref","first-page":"28","DOI":"10.1111\/j.1365-2133.1992.tb00006.x","article-title":"Pharmacokinetics of terbinafine in the nail","volume":"126","author":"Finlay","year":"1992","journal-title":"Br J Dermatol"},{"key":"10.1111\/j.1439-0507.2011.02038.x-BIB22|cit22","doi-asserted-by":"crossref","first-page":"523","DOI":"10.1111\/j.1439-0507.2008.01509.x","article-title":"Usefulness and pharmacokinetic study of oral terbinafine for hyperkeratotic-type tinea pedis","volume":"51","author":"Kikuchi","year":"2008","journal-title":"Mycoses"},{"key":"10.1111\/j.1439-0507.2011.02038.x-BIB23|cit23","article-title":"Onychomycosis observed in children over a 20-year period","author":"Rodr\u00edguez-Pazos","year":"2010","journal-title":"Mycoses"},{"key":"10.1111\/j.1439-0507.2011.02038.x-BIB24|cit24","doi-asserted-by":"crossref","first-page":"313","DOI":"10.3855\/jidc.130","article-title":"Superficial fungal infections: clinical and epidemiological study in adolescents from marginal districts of Lima and Callao, Peru","volume":"3","author":"Flores","year":"2009","journal-title":"J Infect Dev Ctries"},{"key":"10.1111\/j.1439-0507.2011.02038.x-BIB25|cit25","first-page":"860","article-title":"A prospective epidemiological study on tinea pedis and onychomycosis in Hong Kong","volume":"115","author":"Cheng","year":"2002","journal-title":"Chin Med J (Engl)"},{"key":"10.1111\/j.1439-0507.2011.02038.x-BIB26|cit26","doi-asserted-by":"crossref","first-page":"641","DOI":"10.1067\/mjd.2000.107754","article-title":"A large-scale North American study of fungal isolates from nails: the frequency of onychomycosis, fungal distribution, and antifungal susceptibility patterns","volume":"43","author":"Ghannoum","year":"2000","journal-title":"J Am Acad Dermatol"},{"key":"10.1111\/j.1439-0507.2011.02038.x-BIB27|cit27","doi-asserted-by":"crossref","first-page":"341","DOI":"10.1007\/BF00449429","article-title":"Quality of life of persons with onychomycosis","volume":"2","author":"Lubeck","year":"1993","journal-title":"Qual Life Res"},{"key":"10.1111\/j.1439-0507.2011.02038.x-BIB28|cit28","doi-asserted-by":"crossref","first-page":"3226","DOI":"10.1128\/JCM.38.9.3226-3230.2000","article-title":"Prevalence and risk factors of tinea unguium and tinea pedis in the general population in Spain","volume":"38","author":"Perea","year":"2000","journal-title":"J Clin Microbiol"},{"key":"10.1111\/j.1439-0507.2011.02038.x-BIB29|cit29","doi-asserted-by":"crossref","first-page":"701","DOI":"10.1111\/j.0007-0963.2004.05871.x","article-title":"Onychomycosis: the development of a clinical diagnostic aid for toenail disease. Part I. Establishing discriminating historical and clinical features","volume":"150","author":"Fletcher","year":"2004","journal-title":"Br J Dermatol"},{"key":"10.1111\/j.1439-0507.2011.02038.x-BIB30|cit30","doi-asserted-by":"crossref","first-page":"415","DOI":"10.1128\/CMR.11.3.415","article-title":"Onychomycosis: pathogenesis, diagnosis, and management","volume":"11","author":"Elewski","year":"1998","journal-title":"Clin Microbiol Rev"},{"key":"10.1111\/j.1439-0507.2011.02038.x-BIB31|cit31","doi-asserted-by":"crossref","first-page":"490","DOI":"10.1111\/j.1365-2133.1997.tb02128.x","article-title":"Non-dermatophytes in onychomycosis of the toenails","volume":"136","author":"Ellis","year":"1997","journal-title":"Br J Dermatol"},{"key":"10.1111\/j.1439-0507.2011.02038.x-BIB32|cit32","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1111\/j.1529-8019.2007.00109.x","article-title":"Toenail onychomycosis: current and future treatment options","volume":"20","author":"Finch","year":"2007","journal-title":"Dermatol Ther"},{"key":"10.1111\/j.1439-0507.2011.02038.x-BIB33|cit33","doi-asserted-by":"crossref","first-page":"402","DOI":"10.1046\/j.1365-2133.2003.05242.x","article-title":"Guidelines for treatment of onychomycosis","volume":"148","author":"Roberts","year":"2003","journal-title":"Br J Dermatol"},{"key":"10.1111\/j.1439-0507.2011.02038.x-BIB34|cit34","doi-asserted-by":"crossref","first-page":"33","DOI":"10.2165\/00002018-200022010-00004","article-title":"A risk-benefit assessment of the newer oral antifungal agents used to treat onychomycosis","volume":"22","author":"Gupta","year":"2000","journal-title":"Drug Saf"},{"key":"10.1111\/j.1439-0507.2011.02038.x-BIB35|cit35","doi-asserted-by":"crossref","first-page":"811","DOI":"10.1001\/archderm.138.6.811","article-title":"Oral treatments for toenail onychomycosis: a systemic review","volume":"138","author":"Crawford","year":"2002","journal-title":"Arch Dermatol"},{"key":"10.1111\/j.1439-0507.2011.02038.x-BIB36|cit36","doi-asserted-by":"crossref","first-page":"537","DOI":"10.1046\/j.1365-2133.2003.05728.x","article-title":"Cumulative meta-analysis of systemic antifungal agents for the treatment of onychomycosis","volume":"150","author":"Gupta","year":"2004","journal-title":"Br J Dermatol"},{"key":"10.1111\/j.1439-0507.2011.02038.x-BIB37|cit37","doi-asserted-by":"crossref","first-page":"198","DOI":"10.4103\/0019-5154.62746","article-title":"A meta-analysis comparing efficacy of continuous terbinafine with intermittent itraconazole for toenail onychomycosis","volume":"55","author":"Trivedi","year":"2010","journal-title":"Indian J Dermatol"},{"key":"10.1111\/j.1439-0507.2011.02038.x-BIB38|cit38","doi-asserted-by":"crossref","first-page":"262","DOI":"10.4103\/0378-6323.16619","article-title":"An open randomized comparative study of oral itraconazole pulse and terbinafine pulse in the treatment of onychomycosis","volume":"71","author":"Minati","year":"2005","journal-title":"Indian J Dermatol Venereol Leprol"},{"key":"10.1111\/j.1439-0507.2011.02038.x-BIB39|cit39","doi-asserted-by":"crossref","first-page":"375","DOI":"10.1016\/j.det.2006.03.010","article-title":"Therapies for onychomycosis: a review","volume":"24","author":"Gupta","year":"2006","journal-title":"Dermatol Clin"},{"key":"10.1111\/j.1439-0507.2011.02038.x-BIB40|cit40","doi-asserted-by":"crossref","first-page":"658","DOI":"10.1111\/j.1365-2230.2009.03698.x","article-title":"In vitro activity of fluconazole, itraconazole, voriconazole and terbinafine against fungi causing onychomycosis","volume":"35","author":"Bueno","year":"2010","journal-title":"Clin Exp Dermatol"},{"key":"10.1111\/j.1439-0507.2011.02038.x-BIB41|cit41","doi-asserted-by":"crossref","first-page":"958","DOI":"10.1016\/S0190-9622(96)90120-6","article-title":"Treatment of Candida nail infection with terbinafine","volume":"35","author":"Segal","year":"1996","journal-title":"J Am Acad Dermatol"},{"key":"10.1111\/j.1439-0507.2011.02038.x-BIB42|cit42","doi-asserted-by":"crossref","first-page":"16","DOI":"10.1111\/j.1365-2133.1994.tb06088.x","article-title":"Terbinafine in onychomycosis with involvement by non-dermatophytic fungi","volume":"130","author":"Nolting","year":"1994","journal-title":"Br J Dermatol"},{"key":"10.1111\/j.1439-0507.2011.02038.x-BIB43|cit43","doi-asserted-by":"crossref","first-page":"206","DOI":"10.1007\/s102270000019","article-title":"Itraconazole and terbinafine treatment of some nondermatophyte molds causing onychomycosis of the toes and a review of the literature","volume":"5","author":"Gupta","year":"2001","journal-title":"JCMS"},{"key":"10.1111\/j.1439-0507.2011.02038.x-BIB44|cit44","doi-asserted-by":"crossref","first-page":"115","DOI":"10.1111\/j.1439-0507.1999.tb00026.x","article-title":"Activity of terbinafine against serious fungal pathogens","volume":"42","author":"Ryder","year":"1999","journal-title":"Mycoses"},{"key":"10.1111\/j.1439-0507.2011.02038.x-BIB45|cit45","doi-asserted-by":"crossref","first-page":"104","DOI":"10.1159\/000079593","article-title":"Clinical and histological aspects of toenail onychomycosis caused by Aspergillus spp.: 34 cases treated with weekly intermittent terbinafine","volume":"209","author":"Gianni","year":"2004","journal-title":"Dermatology"},{"key":"10.1111\/j.1439-0507.2011.02038.x-BIB46|cit46","doi-asserted-by":"crossref","first-page":"1273","DOI":"10.1111\/j.1468-3083.2009.03306.x","article-title":"Terbinafine (250\u2003mg\/day): an effective and safe treatment of cutaneous sporotrichosis","volume":"23","author":"Francesconi","year":"2009","journal-title":"J Eur Acad Dermatol Venereol"},{"key":"10.1111\/j.1439-0507.2011.02038.x-BIB47|cit47","doi-asserted-by":"crossref","first-page":"1442","DOI":"10.1111\/j.1468-3083.2010.03666.x","article-title":"In vitro antifungal susceptibility of dermatophyte strains causing tinea pedis and onychomycosis in patients with non-insulin-dependent diabetes mellitus: a case-control study","volume":"24","author":"\u00d6zcan","year":"2010","journal-title":"J Eur Acad Dermatol Venereol"},{"key":"10.1111\/j.1439-0507.2011.02038.x-BIB48|cit48","doi-asserted-by":"crossref","first-page":"411","DOI":"10.1016\/j.jaad.2009.04.062","article-title":"Long-term follow-up of toenail onychomycosis caused by dermatophytes after successful treatment with systemic antifungal agents","volume":"62","author":"Piraccini","year":"2010","journal-title":"J Am Acad Dermatol"},{"key":"10.1111\/j.1439-0507.2011.02038.x-BIB49|cit49","doi-asserted-by":"crossref","first-page":"740","DOI":"10.1016\/S0190-9622(97)70111-7","article-title":"Oral terbinafine in the treatment of toenail onychomycosis: North American multicenter trial","volume":"37","author":"Drake","year":"1997","journal-title":"J Am Acad Dermatol"},{"key":"10.1111\/j.1439-0507.2011.02038.x-BIB50|cit50","doi-asserted-by":"crossref","first-page":"595","DOI":"10.1016\/S0190-9622(96)80057-0","article-title":"Treatment of dermatophyte nail infections: an open randomized study comparing intermittent terbinafine therapy with continuous terbinafine treatment and intermittent itraconazole therapy","volume":"34","author":"Tosti","year":"1996","journal-title":"J Am Acad Dermatol"},{"key":"10.1111\/j.1439-0507.2011.02038.x-BIB51|cit51","doi-asserted-by":"crossref","first-page":"162","DOI":"10.1159\/000017990","article-title":"Relapses of onychomycosis after successful treatment with systemic antifungals: a three-year follow-up","volume":"197","author":"Tosti","year":"1998","journal-title":"Dermatology"},{"key":"10.1111\/j.1439-0507.2011.02038.x-BIB52|cit52","doi-asserted-by":"crossref","first-page":"259","DOI":"10.1111\/j.1346-8138.1996.tb04009.x","article-title":"Intermittent therapy with terbinafine for dermatophyte toe-onychomycosis: a new approach","volume":"23","author":"Alpsoy","year":"1996","journal-title":"J Dermatol"},{"key":"10.1111\/j.1439-0507.2011.02038.x-BIB53|cit53","doi-asserted-by":"crossref","first-page":"256","DOI":"10.1111\/j.1468-3083.2008.03036.x","article-title":"The use of an intermittent terbinafine regimen for the treatment of dermatophyte toenail onychomycosis","volume":"23","author":"Gupta","year":"2009","journal-title":"J Eur Acad Dermatol Venereol"},{"key":"10.1111\/j.1439-0507.2011.02038.x-BIB54|cit54","doi-asserted-by":"crossref","first-page":"149","DOI":"10.1111\/j.1365-2133.2007.07974.x","article-title":"A multicentre, randomized, controlled study of the efficacy, safety and cost-effectiveness of a combination therapy with amorolfine nail lacquer and oral terbinafine compared with oral terbinafine alone for the treatment of onychomycosis with matrix involvement","volume":"157","author":"Baran","year":"2007","journal-title":"Br J Dermatol"},{"key":"10.1111\/j.1439-0507.2011.02038.x-BIB55|cit55","first-page":"481","article-title":"Ciclopirox topical solution, 8% combined with oral terbinafine to treat onychomycosis: a randomized, evaluator-blinded study","volume":"4","author":"Gupta","year":"2005","journal-title":"J Drugs Dermatol"},{"key":"10.1111\/j.1439-0507.2011.02038.x-BIB56|cit56","doi-asserted-by":"crossref","first-page":"327","DOI":"10.1080\/09546630500420183","article-title":"Combination of oral terbinafine and topical ciclopirox compared to oral terbinafine for the treatment of onychomycosis","volume":"16","author":"Avner","year":"2005","journal-title":"J Dermatolog Treat"},{"key":"10.1111\/j.1439-0507.2011.02038.x-BIB57|cit57","doi-asserted-by":"crossref","first-page":"393","DOI":"10.4103\/0378-6323.37056","article-title":"An open randomized comparative study to test the efficacy and safety of oral terbinafine pulse as a monotherapy and in combination with topical ciclopirox olamine 8% or topical amorolfine hydrochloride 5% in the treatment of onychomycosis","volume":"73","author":"Jaiswal","year":"2007","journal-title":"Indian J Dermatol Venereol Leprol"},{"key":"10.1111\/j.1439-0507.2011.02038.x-BIB58|cit58","doi-asserted-by":"crossref","first-page":"72","DOI":"10.1111\/j.1439-0507.2008.01531.x","article-title":"Treatment of dermatophyte onychomycosis with three pulses of terbinafine (500\u2003mg day for a week)","volume":"52","author":"Takahata","year":"2009","journal-title":"Mycoses"},{"key":"10.1111\/j.1439-0507.2011.02038.x-BIB59|cit59","doi-asserted-by":"crossref","first-page":"753","DOI":"10.1111\/j.1346-8138.2006.00176.x","article-title":"Combination of pulse therapy with terbinafine tablets and topical terbinafine cream for the treatment of dermatophyte onychomycosis: a pilot study","volume":"33","author":"Nakano","year":"2006","journal-title":"J Dermatol"},{"key":"10.1111\/j.1439-0507.2011.02038.x-BIB60|cit60","first-page":"281","article-title":"Tinea capitis: diagnostic criteria and treatment options","volume":"21","author":"Meadows-Oliver","year":"2009","journal-title":"Dermatology Nursing"},{"key":"10.1111\/j.1439-0507.2011.02038.x-BIB61|cit61","doi-asserted-by":"crossref","first-page":"1312","DOI":"10.1542\/peds.2004-0428","article-title":"Griseofulvin versus terbinafine in the treatment of tinea capitis: a meta-analysis of randomized, clinical trials","volume":"114","author":"Fleece","year":"2004","journal-title":"Paediatrics"},{"key":"10.1111\/j.1439-0507.2011.02038.x-BIB62|cit62","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1016\/j.jaad.2008.02.019","article-title":"Terbinafine hydrochloride oral granules versus oral griseofulvin suspension in children with tinea capitis: results of two randomized, investigator-blinded, multicenter, international, controlled trials","volume":"59","author":"Elewski","year":"2008","journal-title":"J Am Acad Dermatol"},{"key":"10.1111\/j.1439-0507.2011.02038.x-BIB63|cit63","doi-asserted-by":"crossref","first-page":"627","DOI":"10.1046\/j.1468-3083.2003.00691.x","article-title":"The efficacy and safety of terbinafine in children","volume":"17","author":"Gupta","year":"2003","journal-title":"J Eur Acad Dermatol Venereol"}],"container-title":["Mycoses"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1111%2Fj.1439-0507.2011.02038.x","content-type":"unspecified","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/onlinelibrary.wiley.com\/wol1\/doi\/10.1111\/j.1439-0507.2011.02038.x\/fullpdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,3,6]],"date-time":"2025-03-06T03:58:45Z","timestamp":1741233525000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1111\/j.1439-0507.2011.02038.x"}},"subtitle":["Terbinafine use in onychomycosis and tinea capitis"],"short-title":[],"issued":{"date-parts":[[2011,6,12]]},"references-count":63,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2011,11]]}},"URL":"https:\/\/doi.org\/10.1111\/j.1439-0507.2011.02038.x","relation":{},"ISSN":["0933-7407"],"issn-type":[{"value":"0933-7407","type":"print"}],"subject":[],"published":{"date-parts":[[2011,6,12]]}}}